2 hours ago
- On the Move
Comments
koto_feja/E+ via Getty Images
ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of its bladder cancer therapy, Anktiva.
Citing the updated 2026 NCCN
